Publication Date:
2007-11-16
Description:
Background: The prognostic significance of the expression pattern of certain cell surface markers in acute myeloid leukemia (AML) is controversial. Objectives: Analyze the impact of the expression of certain cell surface markers on complete remission rate (CR) and relapse free survival (RFS), in a large series of adult patients with non-promyelocytic AML treated with intensive chemotherapy. Methods: From 1989 to 2007, 451 adult patients (median age 57 years, range 15–80 years) diagnosed with non-promyelocytic AML, received first induction chemotherapy in our institution. Induction therapy consisted of the combination of cytarabine and anthracycline with or without a third agent in 95% of patients and other regimens in the remaining 5%. The post-remission treatment consisted of consolidation chemotherapy followed or not by stem cell transplantation. The inmunophenotypic analysis of bone marrow samples at diagnosis was evaluable in 395 patients (88%). Positivity was defined as more than 20% blasts expressing a specific antigen. It was possible to evaluate the percentage of positive blasts for the following antigens: CD33 (395 patients), CD13 (391), HLA-DR (382), CD14 (375), CD34 (364), CD7 (354), CD11b (350), CD4 (347), CD36 (343), CD15 (326), CD9 (321), CD2 (315), CD38 (250), CD71 (233), myeloperoxidase (MPX) (186), CD117 (178) and CD56 (173). We conducted a univariate and mutivariate analysis in order to define the impact of the expression of cell surface markers on CR rate and RFS. Results: Overall, 256 patients (58.3%) achieved a CR. The following characteristics were associated with a lower probability of CR: age 〉60 years, performance status by means of ECOG scale ≥2, peroxidase staining in
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine